DNASE2 and metabolic dysfunction-associated steatotic liver disease: Although promising, ACCi-based therapies also present important limitations: To date, studies on DNL rates in human subjects are limited to small cohorts and it remains unclear whether DNL dysregulation is a broad feature for patients with MASLD or a specific characteristic of subsets of patients.